1. Introduction {#sec1-viruses-11-01160}
===============

Porcine reproductive and respiratory syndrome (PRRS), caused by PRRS virus (PRRSV), is an economically important viral disease all over the word \[[@B1-viruses-11-01160],[@B2-viruses-11-01160]\]. PRRSV is a member of the *Arteriviridae* family in the order *Nidovirales* and consists of an enveloped 15 kb positive-strand RNA genome containing at least ten open reading frames (ORFs) \[[@B3-viruses-11-01160],[@B4-viruses-11-01160],[@B5-viruses-11-01160],[@B6-viruses-11-01160]\]. PRRSV is divided into two genotypes: the European genotype (type 1) and the North American genotype (type 2). There is considerable sequence variability within both groups, and only about 50--60% nucleotide sequence identity between the two subtypes \[[@B7-viruses-11-01160],[@B8-viruses-11-01160]\]. Recently, based on a new proposed classification scheme, type 1 and type 2 PRRSV have been classified into two species and renamed PRRSV-1 and PRRSV-2, respectively \[[@B9-viruses-11-01160],[@B10-viruses-11-01160]\]. PRRSV has genetic diversity and has evolved multiple mechanisms to evade the host immune response \[[@B11-viruses-11-01160],[@B12-viruses-11-01160]\]. Currently, there are no effective control strategies against PRRS.

Type I interferons (IFN-α/β) play pivotal roles in the innate defense against viral infection. During virus infection, viral nucleic acids are the main pathogen-associated molecular patterns (PAMPs) which can be detected by the cellular receptors such as retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) and interferon gamma-inducible protein 16 (IFI16) (DNA sensor). Then, RIG-I recruits the mitochondrial antiviral signaling (MAVS), while IFI16 activates the endoplasmic reticulum signaling adaptor STING, leading to TANK-binding kinase 1 (TBK1)-dependent phosphorylation of interferon regulatory factor 3 (IRF3) and transcription of type I interferons (IFNs) \[[@B13-viruses-11-01160],[@B14-viruses-11-01160],[@B15-viruses-11-01160],[@B16-viruses-11-01160]\]. Then, type I interferons bind to IFN-α/β receptors and induce the production of a large number of interferon-stimulated genes (ISGs) in response to virus \[[@B17-viruses-11-01160]\].

Previous studies have demonstrated that IFN-α, IFN-β, and IFN-γ have an antiviral effect against PRRSV-2 \[[@B18-viruses-11-01160],[@B19-viruses-11-01160],[@B20-viruses-11-01160],[@B21-viruses-11-01160],[@B22-viruses-11-01160]\]. In addition, interferon-stimulated genes (such as *OAS1* and *Mx2*) have been confirmed to have antiviral effects against type 2 PRRSV strain S1 and PRRSV-WUH3 strain \[[@B23-viruses-11-01160],[@B24-viruses-11-01160]\], which indicated that interferon-stimulated genes play important roles in inhibiting PRRSV replication. IFI16, a member of the PYHIN protein family that contains a pyrin domain and two DNA-binding HIN domains, displays multifaceted activity due to its ability to bind to various target proteins and, in turn, modulate various functions including direct actions in regulation of transcription, proliferation, differentiation, apoptosis, antiviral restriction, and inflammation \[[@B25-viruses-11-01160],[@B26-viruses-11-01160],[@B27-viruses-11-01160],[@B28-viruses-11-01160]\]. Besides, IFI16 has been reported to have a broader role in the regulation of interferon-stimulated genes expression, leading to responses to not only DNA viruses, but also RNA viruses, such as Sendai virus \[[@B29-viruses-11-01160],[@B30-viruses-11-01160]\]. However, the role of IFI16 in regulating PRRSV replication is unclear. So, this study aimed to explore whether IFI16 could inhibit PRRSV replication.

In this study, we have shown that IFI16 could suppress PRRSV-2 replication for the first time. Besides, IFI16 could positively regulate MAVS-mediated type I IFN signaling pathway and interact with MAVS. Furthermore, MAVS was essential for IFI16 to inhibit PRRSV-2 replication, which suggested that IFI16 plays an important role in the antiviral response to PRRSV-2, and these findings may have implications for the future control of PRRS.

2. Materials and Methods {#sec2-viruses-11-01160}
========================

2.1. Cells and Virus {#sec2dot1-viruses-11-01160}
--------------------

HEK-293T (a human embryonic kidney cell line) and PRRSV permissive MARC-145 (an African green monkey kidney cell line) cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco, Grand Island, NY, USA) supplemented with 10% FBS (Gibco), 100 U/mL penicillin, and 100 µg/mL streptomycin (Gibco) at 37 °C in a humidified atmosphere of 5% CO~2~. PRRSV-2 strain BJ-4 (GenBank No. AF331831) was a kind gift from Prof. Hanchun Yang (China Agricultural University).

2.2. Antibodies and Reagents {#sec2dot2-viruses-11-01160}
----------------------------

Mouse anti-Flag M2 monoclonal antibody, mouse anti-c-Myc monoclonal antibody, anti-Flag affinity gel beads, anti-c-Myc affinity gel beads, and mouse IgG agarose were purchased from Sigma-Aldrich. PRRSV N protein antibody was purchased from GeneTex. Mouse anti-β-actin monoclonal antibody was purchased from GenScript. Rabbit anti-MAVS monoclonal antibody was purchased from Cell Signaling Technology (CST). The secondary antibodies conjugated to HRP were purchased from Jackson Immuno Research. Polyinosinic-polycytidylic acid (polyI:C) was purchased from Sigma-Aldrich. Recombinant human IFN-β was purchased from PEPROTECH. Lipofectamine2000 transfection reagent and Lipofectamine RNAiMAX transfection reagent were purchased from Invitrogen (Carlsbad, CA, USA).

2.3. Plasmids {#sec2dot3-viruses-11-01160}
-------------

To generate IFI16-Myc, the cDNA of IFI16 from MARC-145 cells was amplified and cloned into pCMV-Myc vector (Beyotime, Shanghai, China). The genes of RIG-I, MDA5, MAVS, TBK1, and IRF3 from MARC-145 cells were cloned into pCMV-Flag (Beyotime), creating RIG-I-Flag, MDA5-Flag, MAVS-Flag, TBK1-Flag, and IRF3-Flag respectively. The expression plasmids for 3×Flag-tagged MAVS and MAVS truncations were constructed by standard molecular cloning method from cDNA templates. All constructs were confirmed by DNA sequencing. The IFN-β promoter reporter plasmid (p-284) has been constructed as previous described \[[@B31-viruses-11-01160]\]. All primers used are listed in [Table 1](#viruses-11-01160-t001){ref-type="table"}.

2.4. Gene Silencing with siRNA {#sec2dot4-viruses-11-01160}
------------------------------

The specific siRNAs targeting IFI16, MAVS, and the control siRNA (siNC) were synthesized by GenePharma. The siRNA sequences are as follows: siIFI16, 5′-CCAAGCAGCAGUUGCUUAATT-3′; siMAVS, 5′-GCAUCUCUUCAGUACCCUUTT-3′; the nontargeting control siRNA (siNC), 5′-UUCUCCGAACGUGUCACGUTT-3′. MARC-145 cells were transfected with 50 nM siRNA using Lipofectamine RNAiMAX transfection reagent (Invitrogen, Carlsbad, CA, USA). At 24 h post-transfection (hpt), the transfected cells were infected with PRRSV at a multiplicity of infection (MOI) of 0.1. And then the supernatants and lysates of the cells were collected at 24, 36, and 48 h postinfection (hpi) for further analysis.

2.5. Quantitative Real-Time PCR Analysis {#sec2dot5-viruses-11-01160}
----------------------------------------

Total RNA was extracted from cells using RNeasy Mini Kit (Qiagen), reverse transcription was accomplished with PrimeScript™ RT Master Mix (Perfect Real Time) (Takara, Kyoto, Japan) according to the manufacturer's protocol. And then the samples were subjected to real-time PCR analysis with specific primers by using a Fast Start Universal SYBR Green Master Kit (Roche, Basel, Switzerland) on a 7500 fast RT-PCR system (Applied Biosystems, Foster City, CA, USA). Relative analysis of gene expression was evaluated using the 2^−ΔΔCT^ method, in which target gene expression was normalized by glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression. Primers are shown in [Table 2](#viruses-11-01160-t002){ref-type="table"}.

2.6. Dual Luciferase Reporter Assay {#sec2dot6-viruses-11-01160}
-----------------------------------

MARC-145 cells in 24-well plates were transfected with indicated expression plasmids and IFN-β luciferase reporter plasmids by using Lipofectamine 2000 transfection reagent (Invitrogen). At 36 hpt, the cells were transfected with polyI:C (10 µg/mL) (Sigma-Aldrich, St. Louis, MO, USA) for 12 h, and then the cells were harvested and the luciferase activity was measured by using dual-luciferase reporter assay system (Promega, Madison, WI, USA).

2.7. Co-Immunoprecipitation {#sec2dot7-viruses-11-01160}
---------------------------

HEK-293T cells were transfected with IFI16-Myc and MAVS-3×Flag, MAVS truncations plasmids or control vector. At 48 hpt, the cells were lysed in IP-lysis buffer (Sigma-Aldrich) containing protease inhibitor cocktail (Roche) for 1 h at 4 °C. The lysates were centrifuged at 12,000× *g* for 15 min at 4 °C, and the supernatants were pre-cleared with mouse IgG-Agarose (Sigma-Aldrich) at 4 °C for 2 h. Then, the pre-cleared supernatants were incubated with anti-c-Myc affinity gel beads or anti-Flag affinity gel beads (Sigma-Aldrich) for 4 h or overnight at 4 °C. The precipitates were washed five times with TBS buffer and detected by western blotting.

2.8. Virus Titration {#sec2dot8-viruses-11-01160}
--------------------

Virus titers were determined according to a previous report \[[@B32-viruses-11-01160]\]. Briefly, MARC-145 cells, grown in 96-well plates, were infected with ten-fold serial dilution of samples. After 1 h incubation at 37 °C, the supernatants were replaced with fresh DMEM containing 2% FBS. Five days post infection, the cytopathic effect (CPE) characterized by clumping and shrinkage of cells was obviously visible in MARC-145 cells and the viral titers, expressed as 50% tissue culture infective dose (TCID~50~), calculated according to the method of Reed-Muench \[[@B33-viruses-11-01160]\].

2.9. Statistical Analysis {#sec2dot9-viruses-11-01160}
-------------------------

Statistical graphs were created with GraphPad Prism software, and all data were analyzed using Student's *t* tests as the mean values ± the standard deviations (SD) of at least three independent experiments. The asterisks in the figures indicate significant differences (\*, *p* \< 0.05; \*\*, *p* \< 0.01).

3. Results {#sec3-viruses-11-01160}
==========

3.1. IFI16 Inhibits PRRSV-2 Replication {#sec3dot1-viruses-11-01160}
---------------------------------------

Since type I interferon and interferon-induced genes could efficiently inhibit PRRSV replication in MARC-145 cells \[[@B21-viruses-11-01160],[@B23-viruses-11-01160]\], and it has been reported that IFI16 could be induced by type I interferon \[[@B34-viruses-11-01160],[@B35-viruses-11-01160],[@B36-viruses-11-01160]\], we firstly confirmed whether IFI16 could be induced by type I interferon in MARC-145 cells, and then explored whether IFI16 could inhibit PRRSV replication. MARC-145 cells were treated with IFN-β, and then the expression of IFI16 was detected. Consistent with the results of previous reports, IFN-β could also efficiently induce the expression of IFI16 ([Figure 1](#viruses-11-01160-f001){ref-type="fig"}A), and the expression of IFI16 was enhanced in an IFN-β-dose-dependent manner and peaked at 24 h in MARC-145 cells ([Figure 1](#viruses-11-01160-f001){ref-type="fig"}B). In addition, the transcription level of IFI16 was increased in the cells infected with PRRSV-2 ([Figure 1](#viruses-11-01160-f001){ref-type="fig"}C,D).

Next, to explore whether IFI16 could inhibit PRRSV-2 replication, MARC-145 cells were transfected with IFI16-Myc and control vector for 24 h, and then the cells were infected with PRRSV-2 at a MOI of 0.1. The results in [Figure 2](#viruses-11-01160-f002){ref-type="fig"} show that overexpression of IFI16 reduced the RNA levels of PRRSV ([Figure 2](#viruses-11-01160-f002){ref-type="fig"}A), the PRRSV titers ([Figure 2](#viruses-11-01160-f002){ref-type="fig"}B), and the expression levels of the N protein of PRRSV ([Figure 2](#viruses-11-01160-f002){ref-type="fig"}C,D). To further examine the antiviral effects of IFI16 on PRRSV-2, we used specific siRNA to down-regulate the expression of endogenous IFI16, which led to lower expression of IFI16 than that in cells transfected with control siRNA ([Figure 3](#viruses-11-01160-f003){ref-type="fig"}A). Compared with the nontargeting control siRNA (siNC)-transfected control cells, the RNA levels of PRRSV ([Figure 3](#viruses-11-01160-f003){ref-type="fig"}B), viral titers ([Figure 3](#viruses-11-01160-f003){ref-type="fig"}C), and the expression of N protein ([Figure 3](#viruses-11-01160-f003){ref-type="fig"}D,E) were significantly increased in MARC-145 cells transfected with siIFI16. Together, these results indicated that IFI16 acts as an antiviral protein against PRRSV-2.

3.2. IFI16 Enhances the MAVS-mediated Type I IFN Signaling {#sec3dot2-viruses-11-01160}
----------------------------------------------------------

IFI16 plays an important role in Sendai virus (SeV)-mediated production of type I IFN \[[@B30-viruses-11-01160],[@B37-viruses-11-01160]\], and in light of the fact that PRRSV could slightly induce the production of type I IFN \[[@B31-viruses-11-01160],[@B38-viruses-11-01160]\], we wonder whether IFI16 was useful to the transcription of type I IFN during PRRSV infection. MARC-145 cells were transfected with IFI16-Myc or control vector, and 24 h later, the cells were infected with PRRSV-2 BJ-4 at a MOI of 1. The results showed that IFI16 could enhance PRRSV-induced production of IFN-β ([Figure 4](#viruses-11-01160-f004){ref-type="fig"}).

Given the fact that IFI16 plays a key role in the signaling through RIG-I, and among the different RNA sensors, DExD/H-box RNA helicases of the RLR family have been identified as essential sensors of RNA viruses \[[@B15-viruses-11-01160],[@B30-viruses-11-01160],[@B39-viruses-11-01160],[@B40-viruses-11-01160]\], we explored the role of IFI16 in the RIG-I-mediated signaling pathway. Firstly, we found that IFI16 could enhance polyI:C-induced IFN-β promoter activity and the transcriptional levels of IFN-β ([Figure 5](#viruses-11-01160-f005){ref-type="fig"}A,B). Next, to further investigate the mechanism of IFI16 in enhancing type I IFN signaling, MARC-145 cells were co-transfected with plasmids encoding IFI16, components of RIG-I pathway, and IFN-β reporter plasmid. The results showed that IFI16 greatly enhanced the IFN-β promoter activity, the mRNA transcriptional levels of IFN-β, ISG15, and ISG56 induced by MAVS ([Figure 5](#viruses-11-01160-f005){ref-type="fig"}C--F). Subsequently, cells were co-transfected with MAVS, IFN-β reporter plasmid, and different concentrations of IFI16, and the results showed that IFI16 strongly increased MAVS-mediated IFN-β promoter activity and the mRNA transcription levels of IFN-β, ISG15, and ISG56 in a dose-dependent manner ([Figure 5](#viruses-11-01160-f005){ref-type="fig"}G--J).

Since IFI16 could enhance MAVS-mediated type I IFN signaling, to identify whether MAVS is indispensable for IFI16 to regulate the production of type I IFN, MARC-145 cells were transfected with siMAVS, IFI16-Myc, and IFN-β reporter plasmid, and 36 h later, the cells were stimulated with polyI:C. And the results showed that IFI16 could not promote polyI:C-induced type I IFN production upon silencing of MAVS ([Figure 5](#viruses-11-01160-f005){ref-type="fig"}K,L). Collectively, these data indicated that IFI16 positively regulates MAVS-mediated type I IFN signaling.

3.3. IFI16 Interacts with MAVS {#sec3dot3-viruses-11-01160}
------------------------------

IFI16 is mainly localized in nucleus and partially localized in cytoplasmic and mitochondria \[[@B29-viruses-11-01160]\], while MAVS could localize in cytoplasmic and mitochondria \[[@B41-viruses-11-01160]\]. Besides, IFI16 could facilitate the MAVS-mediated type I IFN signaling, so to determine whether IFI16 could interact with MAVS, the co-immunoprecipitation assays (co-IP) were performed in 293T cells, and the results showed that IFI16 specifically interacted with MAVS ([Figure 6](#viruses-11-01160-f006){ref-type="fig"}A,B).

As a central adaptor of IFN signaling, MAVS contains an N-terminal CARD domain, a proline-rich domain, and a C-terminal transmembrane domain (TM) \[[@B42-viruses-11-01160],[@B43-viruses-11-01160]\]. So, to determine the functions of MAVS domains in the binding with IFI16, a series of MAVS truncations were generated ([Figure 6](#viruses-11-01160-f006){ref-type="fig"}C). In the assays of co-IP, IFI16 only interacted with full-length MAVS, but not with truncations of MAVS ([Figure 6](#viruses-11-01160-f006){ref-type="fig"}D). These results indicated that the CARD domain and TM domain of MAVS are sufficient and efficient for the binding with IFI16.

3.4. Antiviral Activity of IFI16 is Dependent on MAVS {#sec3dot4-viruses-11-01160}
-----------------------------------------------------

Since IFI16 possesses significant antiviral activity and enhances MAVS-mediated type I IFN signaling, to investigate whether the antiviral activity of IFI16 is dependent on MAVS, we silenced MAVS using siRNAs, and as shown in [Figure 7](#viruses-11-01160-f007){ref-type="fig"}, marked reduction of MAVS expression was observed in the MAVS silenced cells ([Figure 7](#viruses-11-01160-f007){ref-type="fig"}A,B). And, IFI16 could not decrease the PRRSV RNA levels ([Figure 7](#viruses-11-01160-f007){ref-type="fig"}C), PRRSV titers ([Figure 7](#viruses-11-01160-f007){ref-type="fig"}D), and the expression of N protein of PRRSV ([Figure 7](#viruses-11-01160-f007){ref-type="fig"}E--G) in the MAVS-silenced cells. These data indicated that the anti-PRRSV activity of IFI16 needs the involvement of MAVS.

4. Discussion {#sec4-viruses-11-01160}
=============

In this study, we revealed a novel mechanism by which IFI16 inhibits PRRSV-2 replication. Initially, we showed that IFI16 could efficiently repress PRRSV-2 replication. Subsequently, we demonstrated that IFI16 markedly enhances MAVS-mediated type I IFN signaling and binds directly with MAVS. Finally, the ability of IFI16 to antagonize the replication of PRRSV-2 is dependent on MAVS. Taken together, these findings suggest that IFI16 plays an important role in response to PRRSV-2 in MARC-145 cells.

IFI16 is an intracellular DNA sensor and could mediate the induction of IFN-β by stimulating with single-stranded and double-stranded DNA sequences or DNA virus infection \[[@B29-viruses-11-01160]\]. And IFI16 has also been described as an antiviral restriction factor against DNA viruses since it could directly interact with DNA virus components and block viral replication \[[@B44-viruses-11-01160],[@B45-viruses-11-01160]\]. Besides, IFI16 plays a broader role in the regulation of the type I IFN response to DNA viruses in antiviral immunity \[[@B30-viruses-11-01160]\]. However, the functions of IFI16 in regulating RNA virus including PRRSV replication are largely unknown. In this study, we provide the first evidence that IFI16 could inhibit PRRSV-2 replication in MARC-145 cells. Additionally, IFI16 is widely expressed in endothelial and epithelial cells \[[@B46-viruses-11-01160]\], and although the roles of IFI16 in porcine alveolar macrophages (PAMs) currently could not be investigated, this study may have implications for other RNA viruses.

It has been reported that IFI16 was essential for SeV-mediated production of type I IFN \[[@B30-viruses-11-01160],[@B37-viruses-11-01160]\], and SeV-mediated induction of type I IFN comes primarily from RIG-I activation \[[@B39-viruses-11-01160],[@B40-viruses-11-01160],[@B47-viruses-11-01160]\], which indicated that IFI16 may be involved in regulating the RIG-I signal pathway. Here, we have shown that IFI16 could interact with MAVS and promote MAVS-mediated type I IFN signaling, and MAVS was essential for IFI16 to regulate type I IFN signaling. MAVS is a central adaptor protein for RIG-I signaling pathway, which indicted that IFI16 may positively regulate RIG-I signaling pathway. Given that IFI16 transcriptionally regulates ISGs to enhance IFN responses to DNA viruses \[[@B29-viruses-11-01160],[@B30-viruses-11-01160]\], this may be a common mechanism in response to DNA or RNA viruses, which needs further demonstration in other PRRSV strains, and even other RNA viruses.

Since PRRSV could be recognized by RIG-I and induce the production of type I IFN \[[@B31-viruses-11-01160],[@B38-viruses-11-01160]\], and IFI16 could positively regulate the RIG-I signaling pathway, we explored the mechanism by which IFI16 inhibits PRRSV-2 replication. We found that IFI16 could facilitate the PRRSV-mediated induction of IFN-β, interact with MAVS, and the anti-PRRSV activity of IFI16 is dependent on MAVS, which indicted that the ability of IFI16 to inhibit PRRSV-2 replication may be relevant to its role in the type I IFN signaling. Interestingly, IFI16 expression was increased after PRRSV infection, while possibly inhibiting virus replication. However, the mechanisms underlying need to be explored further.

In fact, in contrast to the results that IFI16 plays an important role in SeV-mediated production of type I IFN \[[@B30-viruses-11-01160]\], several other groups have shown that both knockout and knockdown of IFI16 could not influence the ployI:C and SeV-mediated production of type I interferon \[[@B26-viruses-11-01160],[@B29-viruses-11-01160],[@B48-viruses-11-01160]\]. The reason of these different results may be due to different cell lines they used. Here, we showed another piece of evidence that IFI16 may take part in the RIG-I signaling pathway. Previous studies have shown that STING could interact with RIG-I and MAVS, and there was also a marked reduction in the induction of IFN-β by RIG-I and MAVS in the absence of STING \[[@B49-viruses-11-01160],[@B50-viruses-11-01160]\], while Brunette et al. have shown that the IFN response to poly(dA:dT) was reduced by \>99% in STING^−/−^, MAVS^−/−^ macrophages, and DCs, but not in phagocytes deficient in STING alone \[[@B51-viruses-11-01160]\], which indicated that IFI16 may be a crosstalk between RIG-I-MAVS-type I interferon and STING-DNA-sensing pathways \[[@B52-viruses-11-01160]\]. It is well known that IFI16 recruits STING to induce IFN-β transcription, so the roles of IFI16 in the crosstalk between RIG-I-MAVS-RNA-sensing pathways and IFI16-STING-DNA-sensing pathways need further studies.

In conclusion, our data show for the first time that IFI16 could inhibit PRRSV-2 replication in a MAVS-dependent manner, which may have implications for other RNA viruses and contribute to understand the antiviral mechanism, as well as virus--host interactions.
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![Interferon gamma-inducible protein 16 (IFI16) is upregulated upon interferon-beta (IFN-β) and porcine reproductive and respiratory syndrome virus 2 (PRRSV-2) infection. (**A**) MARC-145 cells were treated with different concentrations of IFN-β, and 24 h later, the mRNA levels of IFI16 were detected by RT-qPCR. (**B**) MARC-145 cells were treated with IFN-β (10 ng/mL) for different times as indicated, and the mRNA levels of IFI16 were examined by RT-qPCR. (**C**) MARC-145 cells were infected with PRRSV-2 BJ-4 at a multiplicity of infection (MOI) of 1, the mRNA levels of IFI16 were examined at 0, 6, 12, 24, 36, and 48 hpi by RT-qPCR. (**D**) MARC-145 cells were infected with PRRSV-2 BJ-4 at different MOIs for 24 h, the mRNA levels of IFI16 were examined by RT-qPCR. All experiments were repeated at least three times with similar results. \* *p* \< 0.05, \*\* *p* \< 0.01.](viruses-11-01160-g001){#viruses-11-01160-f001}

![Overexpression of IFI16 inhibits PRRSV-2 replication. MARC-145 cells were transfected with IFI16-Myc or control vector for 24 h, and then infected with PRRSV-2 BJ-4 at a MOI of 0.1 for another 24, 36, and 48 h. (**A**) The RNA levels of PRRSV were assessed by RT-qPCR. (**B**) The virus titers were assayed by TCID~50~ (50% tissue culture infective dose). (**C**) The expression levels of IFI16 and N protein of PRRSV were analyzed by western blotting. (**D**) The relative intensity ratios of N protein were also shown in this figure by using Image J software. All experiments were repeated at least three times with similar results. \* *p* \< 0.05, \*\* *p* \< 0.01.](viruses-11-01160-g002){#viruses-11-01160-f002}

![Knockdown of IFI16 enhances PRRSV-2 growth. (**A**) MARC-145 cells were transfected with siIFI16 or a nontargeting control (siNC) for 48 h, the knockdown efficiency of IFI16 was examined by RT-qPCR. (**B**) MARC-145 cells transfected with siIFI16 or siNC were infected with PRRSV-2 BJ-4 at a MOI of 0.1 for 24, 36, 48 h. The mRNA levels of IFI16 and PRRSV ORF7 were assessed by RT-qPCR. (**C**) The virus titers were analyzed by TCID~50~. (**D**) The expression levels of N protein were detected by western blotting with a rabbit anti-PRRSV N protein polyclonal antibody. (**E**) The relative intensity ratios of N protein were analyzed by Image J software. All experiments were repeated at least three times with similar results. \* *p* \< 0.05, \*\* *p* \< 0.01.](viruses-11-01160-g003){#viruses-11-01160-f003}

![IFI16 enhances PRRSV-induced production of IFN-β. (**A**) MARC-145 cells were transfected with IFI16-Myc or control vector and IFN-β reporter plasmid, and 24 h later, the cells were infected with PRRSV-2 BJ-4 at a MOI of 1 for 12 h or 24 h, and then the luciferase activities were assayed. (**B**) MARC-145 cells were transfected with IFI16-Myc or control vector for 24 h, then infected with PRRSV-2 BJ-4 at a MOI of 1 for 12 h or 24 h, and the mRNA levels of IFN-β were measured by RT-qPCR. All experiments were repeated at least three times with similar results. \* *p* \< 0.05, \*\* *p* \< 0.01.](viruses-11-01160-g004){#viruses-11-01160-f004}

![IFI16 enhances MAVS-mediated type I IFN signaling. (**A**) MARC-145 cells were transfected with IFN-β reporter plasmid and IFI16-Myc or control vector, and 36 h later, the cells were transfected with polyI:C (10 µg/mL) for 12 h, and then the luciferase activities were assayed. (**B**) MARC-145 cells were transfected with IFI16-Myc or control vector for 36 h, then transfected with polyI:C for 12 h, the mRNA levels of IFN-β were measured by RT-qPCR. (**C**) MARC-145 cells were transfected with IFN-β reporter plasmid, IFI16-Myc, and IRF3, MAVS, TBK1, RIG-I, or MDA5 plasmids. Luciferase assays were performed at 48 h. (**D**--**F**) MARC-145 cells were transfected with IFI16-Myc and IRF3, MAVS, TBK1, RIG-I, or MDA5 plasmids. The mRNA levels of IFN-β (**D**), ISG15 (**E**), and ISG56 (**F**) were detected by RT-qPCR. (**G**) MARC-145 cells were transfected with IFN-β reporter plasmid, MAVS, and increasing amounts of IFI16-Myc, at 48 hpt, the luciferase activities were analyzed using a dual-luciferase reporter assay. (**H**--**J**) MARC-145 cells were transfected with MAVS and increasing amounts of IFI16-Myc, the mRNA levels of IFN-β (**H**), ISG15 (**I**), and ISG56 (**J**) were detected by RT-qPCR. (**K**) MARC-145 cells were transfected with IFN-β reporter plasmid, IFI16-Myc, and siNC or siMAVS for 36 h, then the cells were stimulated with polyI:C, and 12 h later, the luciferase activities were assayed. (**L**) MARC-145 cells were transfected with IFI16-Myc and siNC or siMAVS for 36 h, and then the cells were stimulated with polyI:C, and 12 h later, the mRNA levels of IFN-β were quantified by RT-qPCR. All experiments were repeated at least three times with similar results. \* *p* \< 0.05, \*\* *p* \< 0.01.](viruses-11-01160-g005){#viruses-11-01160-f005}

![IFI16 interacts with MAVS. (**A**,**B**) HEK-293T cells were co-transfected with IFI16-Myc and MAVS-3×Flag for 48 h. Cells were lysed, and the lysates were subjected to immunoprecipitation and analyzed by western blotting using indicated antibodies. (**C**) Scheme of MAVS protein and its mutants. (**D**) HEK-293T cells were co-transfected with IFI16-Myc and MAVS-3×Flag, MAVS-1-3×Flag, MAVS-2-3×Flag, MAVS-3-3×Flag, p3×Flag-CMV-7.1, and 48 h later, the cells were lysed and subjected to immunoprecipitation and analyzed by western blotting.](viruses-11-01160-g006){#viruses-11-01160-f006}

![The antiviral activity of IFI16 is dependent on MAVS. (**A**,**B**) MARC-145 cells were transfected with siMAVS or siNC for 48 h, the silence efficiency of MAVS was examined by RT-qPCR and western blotting. (**C**) MARC-145 cells were transfected with siMAVS and IFI16-Myc, and 24 h later, and the cells were infected with PRRSV-2 BJ-4 at a MOI of 0.1 for 24 h. Then, the cells were harvested, and RNA levels of PRRSV were determined by RT-qPCR. (**D**) The virus titers from cell supernatants were analyzed by TCID~50~. (**E**) The expression levels of N protein were detected by western blotting. (**F**,**G**) The relative intensity ratios of MAVS and N protein were analyzed using Image J software. All experiments were repeated at least three times with similar results. \* *p* \< 0.05, \*\* *p* \< 0.01.](viruses-11-01160-g007){#viruses-11-01160-f007}

viruses-11-01160-t001_Table 1

###### 

Primers used for expression plasmid construction.

  Primers    Sequences (5′ to 3′)
  ---------- ---------------------------------------
  IFI16-F    CGCGGATCCATGGAAAAAAAATACAAGAACATTG
  IFI16-R    CCGCTCGAGTTAGAAGAAAAAGCCTGGTGAAGTT
  RIG-I-F    TCCCCCCGGGCATGACTACGGAGCAGCGGCGCAGCCT
  RIG-I-R    ATCTGTCGACTCATTTGGCCATTTCTGCTGGAT
  MDA5-F     CGCGGATCCATGTCGAATGGGTATTCCACAGAC
  MDA5-R     CCGCTCGAGCTAATCCTCATCACTAAATAAACAGCA
  MAVS-F     CCCAAGCTTATGCCGTTTGCTGAAGACAAGACCT
  MAVS-R     CCGCTCGAGCTAGTGCAGGCGCCGCCGGTACATC
  IRF3-F     CCCAAGCTTATGGGAACCCCAAAGCCACGGAT
  IRF3-R     CCGCTCGAGTCAGGTCTCCCCAGGGCCCTGGAA
  TBK1-F     CGCGGATCCATGCAGAGCACTTCTAATCATCT
  TBK1-R     CCGCTCGAGCTAAAGACAGTCAACGTTGCGA
  MAVS-1-F   CCCAAGCTTATGCCGTTTGCTGAAGACAAGACCT
  MAVS-1-R   CGGGGTACCCTAGTGGCATGGCCCCTCCCTCT
  MAVS-2-F   CCCAAGCTTATGTACCAGCCTCGGACCTCGGAC
  MAVS-2-R   CGGGGTACCCTAGTGCAGGCGCCGCCGGTACATC
  MAVS-3-F   CCCAAGCTTATGTCCTCTGACCTGGCAGCCCTC
  MAVS-3-R   CGGGGTACCCTAGTGCAGGCGCCGCCGGTACATC

viruses-11-01160-t002_Table 2

###### 

Primers used for qPCR.

  Primers   Sequences (5′ to 3′)       Amplicon Size   Final Concentration
  --------- -------------------------- --------------- ---------------------
  ORF7-F    AAACCAGTCCAGAGGCAAGG       221             0.3 µM
  ORF7-R    GCAAACTAAACTCCACAGTGTAA                    
  IFI16-F   TGTGAATGGGGTGTTTGAGGT      169             0.3 µM
  IFI16-R   CGGTGCCAATTCAAAGCAGG                       
  IFN-β-F   ACGGCTCTTTCCATGAGCTAC      185             0.3 µM
  IFN-β-R   GTCAATGCAGCGTCCTCCTT                       
  ISG15-F   CTGAAGGCAAAGATCGCCCA       186             0.3 µM
  ISG15-R   GTCGTTCCTCACCAGGATGC                       
  ISG56-F   AGGAAACACCCACTTCGGTC       100             0.3 µM
  ISG56-R   CCTCTAGGCTGCCCTTTTGT                       
  MAVS-F    CTGCCTCACAGCAAGAGACCA      181             0.3 µM
  MAVS-R    GTAGACACAGGCCACTTCGTC                      
  GAPDH-F   GAAGGTGAAGGTCGGAGTCA       133             0.3 µM
  GAPDH-R   CATGTAAACCATGTAGTTGAGGTC                   

[^1]: These authors contributed equally to this work.
